IKK  programs to turn on the GADD45 -MKK4-JNK apoptotic cascade specifically via p50 NF- B in arsenite response

L. Song,J. Li,D. Zhang,Z.-g. Liu,J. Ye,Q. Zhan,H.-M. Shen,M. Whiteman,C. Huang

DOI: https://doi.org/10.1083/jcb.200602149

2006-01-01

Abstract:Cross talk between NF-kappa B and c-Jun N-terminal kinases (JNKs) has been implicated in the cell life and death decision under various stresses. Functional suppression of JNK activation by NF-kappa B has recently been proposed as a key cellular survival mechanism and contributes to cancer cells escaping from apoptosis. We provide a novel scenario of the proapoptotic role of I kappa B kinase beta (IKK beta)-NF-K kappa B, which can act as the activator of the JNK pathway through the induction of GADD45 alpha for triggering MKK4/JNK activation, in response to the stimulation of arsenite, a cancer therapeutic reagent. This effect of IKK beta-NF-kappa B is dependent on p50 but not the p65/relA NF-kappa B subunit, which can Increase the stability of GADD45 alpha protein through suppressing its ubiquitination and proteasome-dependent degradation. IKK beta-NF-kappa B can therefore either activate or suppress the JNK cascade and consequently mediate pro- or antiapoptotic effects, depending on the manner of its induction. Furthermore, the NF-kappa B p50 subunit can exert a novel regulatory function on protein modification independent of the classical NF-kappa B transcriptional activity.